SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) and P3 Health Partners (NASDAQ:PIII – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.
Risk and Volatility
SOPHiA GENETICS has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
Earnings and Valuation
This table compares SOPHiA GENETICS and P3 Health Partners”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $65.17 million | 5.24 | -$62.49 million | ($0.46) | -10.98 |
| P3 Health Partners | $1.50 billion | 0.03 | -$135.85 million | ($40.18) | -0.13 |
SOPHiA GENETICS has higher earnings, but lower revenue than P3 Health Partners. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings for SOPHiA GENETICS and P3 Health Partners, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 1 | 0 | 2 | 0 | 2.33 |
| P3 Health Partners | 1 | 0 | 1 | 0 | 2.00 |
SOPHiA GENETICS currently has a consensus target price of $9.00, suggesting a potential upside of 78.22%. P3 Health Partners has a consensus target price of $12.50, suggesting a potential upside of 135.85%. Given P3 Health Partners’ higher possible upside, analysts plainly believe P3 Health Partners is more favorable than SOPHiA GENETICS.
Profitability
This table compares SOPHiA GENETICS and P3 Health Partners’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -41.13% | -37.75% | -18.75% |
| P3 Health Partners | -9.07% | -302.33% | -16.72% |
Insider and Institutional Ownership
31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 17.8% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
SOPHiA GENETICS beats P3 Health Partners on 8 of the 14 factors compared between the two stocks.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
About P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
